Skip to main content
Clinical Trials/CTRI/2023/02/049898
CTRI/2023/02/049898
Recruiting
Phase 3

A COMPARISON BETWEEN STANDARD OF CARE TREATMENT AND DAPAGLIFLOZIN ADDED TO STANDARD OF CARE TREATMENT IN LUPUS NEPHRITIS PATIENTS

DR MANISH RATHI0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: M321- Systemic lupus erythematosus withorgan or system involvement
Sponsor
DR MANISH RATHI
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
DR MANISH RATHI

Eligibility Criteria

Inclusion Criteria

  • ALL NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS WITH BIOPSY PROVEN LUPUS NEPHRITIS (CLASS III,IV,V,III\+V,IV\+V) ARE ELIGIBLE IF THEY ARE ABOVE 18 YEARS OF AGE

Exclusion Criteria

  • 1\. PATIENTS HAVING PULMONARY ALVEOLAR HEMMORHAGE
  • 2\. PATIENTS WITH NEUROPSYCHIATRIC SLE
  • 3\. PATIENT WITH RAPIDLY PROGRESSIVE RENAL FAILURE
  • 4\. PATIENTS WHO ARE ON HEMODIALYSIS
  • 5\. PATIENTS WITHH eGFR LESS THAN 25 ml/min /1\.73 m2
  • 6\. PATIENTS WITH BASELINE CREATININE MORE THAN 3 mg/dl
  • 7\. PATIENTS UNWILLING TO GIVE CONSENT

Outcomes

Primary Outcomes

Not specified

Similar Trials